BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

BioRelix, Inc. Announces $25.75 Million Series A Financing to Fund Development of Antibiotic Product Pipeline


6/8/2007 1:44:13 PM

NEW HAVEN, Conn.--(BUSINESS WIRE)--BioRelix, Inc., a biopharmaceutical company focused on the development of novel anti-infective agents, announced today the completion of a $25.75 million Series A financing. The financing was led by CHL Medical Partners with participation by new investors New Leaf Venture Partners and Aisling Capital and existing investors Novartis Venture Fund, Elm Street Ventures and Alexandria Real Estate Equities. BioRelix expects to use the funds to build a portfolio of anti-infective product candidates based on novel patented bacterial RNA targets, termed RiboSwitches™, which were identified by the laboratory of BioRelix’ co-founder, Ronald Breaker, Ph.D., Howard Hughes Investigator and Henry Ford II Professor at Yale University.

Read at press release


   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->